Gyre Therapeutics, Inc. (GYRE) stock
GYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/3014% below fair value
$4.34−0.22 (-4.82%)
Close on Nov 18, 2026Market cap $483.95MP/E –Yield –
Gyre Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Gyre Therapeutics's ebitda for the twelve months ending Sep 30, 2026 was -$12.82M, down 355.0% year over year. For fiscal 2025 it was $13.97M, down 21.1% from the year before. The highest annual figure on record is $17.71M in fiscal 2024.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.97M | -21.1% |
| FY2024 | Dec 31, 2024 | $17.71M | – |
| FY2023 | Dec 31, 2023 | -$66.16M | -742.9% |
| FY2022 | Dec 31, 2022 | $10.29M | – |
| FY2021 | Dec 31, 2021 | -$87.60M | – |
| FY2020 | Dec 31, 2020 | -$57.23M | – |
| FY2019 | Dec 31, 2019 | -$57.13M | – |
| FY2018 | Dec 31, 2018 | -$33.67M | – |
| FY2017 | Dec 31, 2017 | -$21.65M | – |
| FY2016 | Dec 31, 2016 | -$20.03M | – |
| FY2015 | Dec 31, 2015 | -$13.33M | – |
| FY2014 | Dec 31, 2014 | -$6.83M | – |
| FY2013 | Dec 31, 2013 | -$9.15M | – |
| FY2012 | Dec 31, 2012 | -$5.93M | – |
| FY2011 | Dec 31, 2011 | -$7.27M | -148.1% |
| FY2010 | Dec 31, 2010 | $15.11M | – |
| FY2009 | Dec 31, 2009 | -$38.49M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$1.05M | -145.3% |
| Q2 FY2026 | Jun 30, 2026 | -$12.88M | – |
| Q1 FY2026 | Mar 31, 2026 | -$8.68M | -409.2% |
| Q4 FY2025 | Dec 31, 2025 | $9.80M | +770.3% |
| Q3 FY2025 | Sep 30, 2025 | $2.32M | -50.4% |
| Q2 FY2025 | Jun 30, 2025 | -$1.23M | -136.0% |
| Q1 FY2025 | Mar 31, 2025 | $2.81M | -66.9% |
| Q4 FY2024 | Dec 31, 2024 | $1.13M | – |
| Q3 FY2024 | Sep 30, 2024 | $4.68M | -63.9% |
| Q2 FY2024 | Jun 30, 2024 | $3.42M | -35.2% |
| Q1 FY2024 | Mar 31, 2024 | $8.49M | +22.3% |
| Q4 FY2023 | Dec 31, 2023 | -$91.33M | – |
| Q3 FY2023 | Sep 30, 2023 | $12.96M | – |
| Q2 FY2023 | Jun 30, 2023 | $5.28M | -89.8% |
| Q1 FY2023 | Mar 31, 2023 | $6.94M | – |
| Q4 FY2022 | Dec 31, 2022 | -$21.59M | – |
| Q3 FY2022 | Sep 30, 2022 | -$5.13M | – |
| Q2 FY2022 | Jun 30, 2022 | $51.60M | – |
| Q1 FY2022 | Mar 31, 2022 | -$14.59M | – |
| Q4 FY2021 | Dec 31, 2021 | -$20.20M | – |
| Q3 FY2021 | Sep 30, 2021 | -$25.14M | – |
| Q2 FY2021 | Jun 30, 2021 | -$19.87M | – |
| Q1 FY2021 | Mar 31, 2021 | -$22.39M | – |
| Q4 FY2020 | Dec 31, 2020 | -$18.80M | – |
| Q3 FY2020 | Sep 30, 2020 | -$16.06M | – |
| Q2 FY2020 | Jun 30, 2020 | -$17.34M | – |
| Q1 FY2020 | Mar 31, 2020 | -$5.04M | – |
| Q4 FY2019 | Dec 31, 2019 | -$13.95M | – |
| Q3 FY2019 | Sep 30, 2019 | -$13.16M | – |
| Q2 FY2019 | Jun 30, 2019 | -$14.35M | – |
| Q1 FY2019 | Mar 31, 2019 | -$15.67M | – |
| Q4 FY2018 | Dec 31, 2018 | -$11.64M | – |
| Q3 FY2018 | Sep 30, 2018 | -$8.31M | – |
| Q2 FY2018 | Jun 30, 2018 | -$7.08M | – |
| Q1 FY2018 | Mar 31, 2018 | -$6.65M | – |
| Q4 FY2017 | Dec 31, 2017 | -$5.79M | – |
| Q3 FY2017 | Sep 30, 2017 | -$5.84M | – |
| Q2 FY2017 | Jun 30, 2017 | -$5.90M | – |
| Q1 FY2017 | Mar 31, 2017 | -$4.12M | – |
| Q4 FY2016 | Dec 31, 2016 | -$5.16M | – |
See a number that looks wrong?